單核吞噬細(xì)胞系統(tǒng)包括單核細(xì)胞、結(jié)締組織和淋巴組織中的巨噬細(xì)胞設備製造、骨組織中的破骨細(xì)胞不斷完善、神經(jīng)組織中的小膠質(zhì)細(xì)胞製度保障、肝庫弗細(xì)胞技術節能、皮膚朗格漢斯細(xì)胞和肺巨噬細(xì)胞。單核吞噬細(xì)胞系統(tǒng)能吞噬清除體內(nèi)病菌異物及衰老傷亡細(xì)胞趨勢，參與非特異性免疫防御機(jī)制精準調控，參與特異性免疫應(yīng)答，發(fā)揮特異性免疫功能等情況正常，是人體中重要的一類保護(hù)性細(xì)胞系統(tǒng)行業分類。

1、單核細(xì)胞：單核細(xì)胞是白細(xì)胞中體積較大的一種提高鍛煉，在機(jī)體發(fā)生炎癥時(shí)進(jìn)入組織內(nèi)發展邏輯，分化為具有活躍吞噬功能的巨噬細(xì)胞；

2有所提升、巨噬細(xì)胞：巨噬細(xì)胞廣泛分布于各器官內(nèi)聽得進，尤其多見于淋巴結(jié)、脾先進水平、肝便利性、骨髓等器官。具有活躍的吞噬能力重要平臺，可識別吞噬細(xì)菌深刻認識、異物、壞死組織等應用提升，是機(jī)體內(nèi)有重要防御功能的細(xì)胞主動性；

3、破骨細(xì)胞：破骨細(xì)胞是骨吸收的主要功能細(xì)胞發展的關鍵，在吸收骨質(zhì)時(shí)具有將基質(zhì)中的鈣離子持續(xù)轉(zhuǎn)移至細(xì)胞外液的特殊功能道路，在骨發(fā)育、生長真諦所在、修復(fù)指導、重建中具有重要作用；

4倍增效應、小膠質(zhì)細(xì)胞：小膠質(zhì)細(xì)胞是腦組織中的神經(jīng)免疫細(xì)胞規則製定，具有吞噬功能，同時(shí)能促進(jìn)神經(jīng)系統(tǒng)的發(fā)育，促進(jìn)神經(jīng)元的存活關規定；

5發展基礎、肝庫弗細(xì)胞：肝巨噬細(xì)胞是肝內(nèi)的巨噬細(xì)胞，能清除從門靜脈入肝的抗原異物建強保護，清除衰老的血細(xì)胞和監(jiān)視腫瘤同期；

6、肺巨噬細(xì)胞：肺巨噬細(xì)胞是參與肺防御免疫功能的重要細(xì)胞之一堅持先行，具有活躍的吞噬功能產業，能吞噬吸入的塵粒、細(xì)菌情況較常見、異物及滲出的紅細(xì)胞可持續。

對于淋巴結(jié)巨噬細(xì)胞的研究，體內(nèi)實(shí)驗(yàn)時(shí)體製，我們會使用荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸鹽脂質(zhì)體構建。如果研究的是實(shí)驗(yàn)性淋巴絲蟲病模型，可以參考如下文獻(xiàn)服務延伸。

論文題目： Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor–mediated lymphangiogenesis

期刊名稱：J Clin Invest.

時(shí)間期卷：2021;131(5):e140853.

在線時(shí)間：2021年1月12日

DOI：doi.org/10.1172/JCI140853.

品牌：Liposoma

貨號：CP-005-005

規(guī)格：5ml+5ml

品名：Clodronate Liposomes  and Control Liposomes

注射方式：s.c.皮下

濃度：2.5mg/ml

次數(shù)：2次

頻率：3天一次

To interrogate the functional role of prolymphangiogenic monocytes and monocyte-derived MΦs recruited to the site of filaria-parasitized lymphatics, we blocked CCR2+ monocyte recruitment following BmL3 infection by administration of an anti-CCR2 ablating antibody (28). In a complementary approach, we reduced total phagocyte cell populations, including monocytes and MΦs, by local subcutaneous administration of clodronate encapsulated in liposomes (Figure 7A). Confirming treatment efficacy, both anti-CCR2 and clodronate liposome treatments delivered to filaria-infected mice successfully reduced circulating blood monocyte populations. Further, anti-CCR2 significantly reduced lymphatic-associated monocyte populations following infection (Figure 7, B and C). Following ablations of monocyte and total phagocyte populations, while remodeled lymphatics were still apparent, the magnitude of lymphatic insufficiency was significantly reduced, as demonstrated by reduced backflow of ICG following anti-CCR2 treatment (Figure 7, F and G) and dermal retention of EB (Figure 7H) following both anti-CCR2 and clodronate liposome treatments. Additionally, dermal lymphatic vessel dilation was significantly reduced following both anti-CCR2 and clodronate liposome treatments (Figure 7, I and J). These ablation experiments indicate a functional role for prolymphangiogenic monocyte populations, after recruitment from the blood to local parasitized lymphatics, in the development of filaria-associated lymphatic dysfunction.

材料和方法：

CCR2 and clodronate liposome monocyte/MΦ depletion experiments.

Following infection, mice were administered either 20 μg MC-21 rat anti–mouse CCR2 depleting antibody (Matthias Mack, Regensburg University; ref. 28) i.p., daily, or 2.5 mg/mL clodronate liposome suspensions (Liposoma) s.c. at BmL3 infection sites every 3 days. Treatment was undertaken for 6 days.